Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pharmacogenomics J
2018 Jan 01;181:136-143. doi: 10.1038/tpj.2016.92.
Show Gene links
Show Anatomy links
Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain.
Teitelbaum AM
,
Murphy SE
,
Akk G
,
Baker TB
,
Germann A
,
von Weymarn LB
,
Bierut LJ
,
Goate A
,
Kharasch ED
,
Bloom AJ
.
???displayArticle.abstract???
A common haplotype of the flavin-containing monooxygenase gene FMO3 is associated with aberrant mRNA splicing, a twofold reduction in in vivo nicotine N-oxidation and reduced nicotine dependence. Tobacco remains the largest cause of preventable mortality worldwide. CYP2A6, the primary hepatic nicotine metabolism gene, is robustly associated with cigarette consumption but other enzymes contribute to nicotine metabolism. We determined the effects of common variants in FMO3 on plasma levels of nicotine-N-oxide in 170 European Americans administered deuterated nicotine. The polymorphism rs2266780 (E308G) was associated with N-oxidation of both orally administered and ad libitum smoked nicotine (P⩽3.3 × 10-5 controlling for CYP2A6 genotype). In vitro, the FMO3 G308 variant was not associated with reduced activity, but rs2266780 was strongly associated with aberrant FMO3 mRNA splicing in both liver and brain (P⩽6.5 × 10-9). Surprisingly, in treatment-seeking European American smokers (n=1558) this allele was associated with reduced nicotine dependence, specifically with a longer time to first cigarette (P=9.0 × 10-4), but not with reduced cigarette consumption. As N-oxidation accounts for only a small percentage of hepatic nicotine metabolism we hypothesized that FMO3 genotype affects nicotine metabolism in the brain (unlike CYP2A6, FMO3 is expressed in human brain) or that nicotine-N-oxide itself has pharmacological activity. We demonstrate for the first time nicotine N-oxidation in human brain, mediated by FMO3 and FMO1, and show that nicotine-N-oxide modulates human α4β2 nicotinic receptor activity in vitro. These results indicate possible mechanisms for associations between FMO3 genotype and smoking behaviors, and suggest nicotine N-oxidation as a novel target to enhance smoking cessation.
Aliverti,
Identifying and quantitating FAD and FMN in simple and in iron-sulfur-containing flavoproteins.
1999, Pubmed
Aliverti,
Identifying and quantitating FAD and FMN in simple and in iron-sulfur-containing flavoproteins.
1999,
Pubmed
Benowitz,
Ethnic differences in N-glucuronidation of nicotine and cotinine.
1999,
Pubmed
Berg,
Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.
2010,
Pubmed
Bhagwat,
Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain.
1996,
Pubmed
Bhamre,
Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes.
1995,
Pubmed
Bierut,
Novel genes identified in a high-density genome wide association study for nicotine dependence.
2007,
Pubmed
Bloom,
Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.
2013,
Pubmed
Bloom,
The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
2011,
Pubmed
Bloom,
A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele.
2013,
Pubmed
Bloom,
Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide.
2014,
Pubmed
Bloom,
The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
2013,
Pubmed
Bloom,
Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6.
2012,
Pubmed
Borland,
The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study.
2010,
Pubmed
Branstetter,
Predictors of the Nicotine Dependence Behavior Time to the First Cigarette in a Multiracial Cohort.
2015,
Pubmed
Cahill,
Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
2013,
Pubmed
Chenoweth,
Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption.
2014,
Pubmed
Cho,
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13.
2012,
Pubmed
Ferguson,
Cytochrome P450 enzymes in the brain: emerging evidence of biological significance.
2011,
Pubmed
Gadel,
Differences in Methadone Metabolism by CYP2B6 Variants.
2015,
Pubmed
Haberstick,
Genes, time to first cigarette and nicotine dependence in a general population sample of young adults.
2007,
Pubmed
Hinrichs,
Common polymorphisms in FMO1 are associated with nicotine dependence.
2011,
Pubmed
Ho,
Overview of the pharmacogenomics of cigarette smoking.
2007,
Pubmed
Hukkanen,
Metabolism and disposition kinetics of nicotine.
2005,
Pubmed
Kang,
Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population.
2000,
Pubmed
Katchamart,
Concurrent flavin-containing monooxygenase down-regulation and cytochrome P-450 induction by dietary indoles in rat: implications for drug-drug interaction.
2000,
Pubmed
Lattard,
Alternative processing events in human FMO genes.
2004,
Pubmed
Lerman,
Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.
2010,
Pubmed
Li,
Activation and modulation of human α4β2 nicotinic acetylcholine receptors by the neonicotinoids clothianidin and imidacloprid.
2011,
Pubmed
McCarthy,
A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling.
2008,
Pubmed
Mokdad,
Actual causes of death in the United States, 2000.
2004,
Pubmed
Murphy,
Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.
2014,
Pubmed
Park,
Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide.
1993,
Pubmed
Piasecki,
Refining the tobacco dependence phenotype using the Wisconsin Inventory of Smoking Dependence Motives: II. Evidence from a laboratory self-administration assay.
2010,
Pubmed
Piasecki,
Tobacco Dependence: Insights from Investigations of Self-Reported Smoking Motives.
2010,
Pubmed
Piper,
Efficacy of bupropion alone and in combination with nicotine gum.
2007,
Pubmed
Piper,
A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.
2009,
Pubmed
Saccone,
The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans.
2009,
Pubmed
Schnoll,
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.
2009,
Pubmed
Shimizu,
Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities.
2007,
Pubmed
Stephens,
A comparison of bayesian methods for haplotype reconstruction from population genotype data.
2003,
Pubmed
Thorgeirsson,
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior.
2010,
Pubmed
Thorgeirsson,
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.
2008,
Pubmed
Tobacco and Genetics Consortium,
Genome-wide meta-analyses identify multiple loci associated with smoking behavior.
2010,
Pubmed
Wang,
Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5.
2009,
Pubmed
Zhang,
An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex.
2014,
Pubmed
Zhang,
Quantitative analysis of FMO gene mRNA levels in human tissues.
2006,
Pubmed
von Weymarn,
Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.
2006,
Pubmed